To QALY or not to QALY—does ICER's methodology risk patient access?

25 January 2019

Love it or loathe it, the Institute for Clinical and Economic Review (ICER) is not about to go away.

Founded in 2006, this small non-profit research organization in Boston, Massachusetts, has quietly taken on a significant amount of sway in pricing negotiations in the enormous US market for prescription pharmaceuticals.

Claiming to be independent and non-partisan, it is financed by a mixture of charitable donations and industry sources. Funding from foundations, which makes up about 80% of the total, comes from the Laura and John Arnold Foundation, the Blue Shield of California Foundation and others.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK